Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma research hub
3 indexed studies · 2 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
Multicenter, open-label, randomized Phase 2 study evaluating continuous weekly dosing of ficerafusp alfa (BCA101) in combination with pembrolizumab versus an alternative dosing regimen for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma
This study tests a new medicine combination for adults with head and neck cancer that has returned or spread. Researchers are combining an experimental drug called ficerafusp alfa with an immunotherapy called pembrolizumab to see which dosing schedule works best to keep the cancer from growing.
Belgium - recruitingTherapeutic confirmatory (Phase III)
The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is looking at a new drug called Buparlisib, combined with a standard chemotherapy drug, Paclitaxel. It's for people with a type of head and neck cancer that has come back or spread. Researchers want to see if this combination helps people live longer compared to Paclitaxel alone.
Germany · Italy · Hungary - recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
This study is looking for new treatment combinations for head and neck cancer that has come back or spread. It's a Phase 2 trial, meaning researchers want to see how well these new drug combinations work and if they are safe.
Italy · Spain · France